Brainstorm cell therapeutics submits special protocol assessment (spa) request to fda for phase 3b trial of nurown® in als

New york , feb. 23, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has submitted a special protocol assessment (spa) request to the u.s. food and drug administration (fda) for a phase 3b study of nurown®, its investigational treatment for amyotrophic lateral sclerosis (als). the submission follows an in-person meeting that brainstorm held with the fda in december 2023.
BCLI Ratings Summary
BCLI Quant Ranking